SCHEMBL2898100

SCHEMBL2898100

COCC(C)n1c(=O)c(O)c2n(c1=O)CCN(Cc1ccc(F)cc1)C2=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP2D6 P10635 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
KCNH2 Q12809 1/20 0.39
GRM2 Q14416 1/20 0.39
TP53 P04637 3/20 0.39
RAB9A P51151 1/20 0.36
ALDH1A1 P00352 3/20 0.36
POLB P06746 1/20 0.36
AKR1B1 P15121 1/20 0.35
LMNA P02545 3/20 0.34
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPC1 O15118 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2898168 0.80 KCNH2 (0.41) MEN1KMT2ACYP2D6HRH3KCNH2
SCHEMBL2890924 0.79 KCNH2 (0.45) MEN1KMT2ACYP2D6HRH3KCNH2
SCHEMBL2898490 0.79 KCNH2 (0.41) MEN1KMT2ACYP2D6HRH3KCNH2
SCHEMBL2894842 0.78 HTT (0.40) MEN1KMT2ACYP2D6HRH3KCNH2
SCHEMBL2899665 0.77 KCNH2 (0.41) CYP2D6HRH3KCNH2GRM2TP53
SCHEMBL2895650 0.76 MAOB (0.38) CYP2D6HRH3KCNH2GRM2TP53
SCHEMBL2892100 0.76 TP53 (0.46) MEN1KMT2ACYP2D6HRH3TP53
SCHEMBL3902833 0.74 GRM2 (0.47) MEN1KMT2ACYP2D6HRH3KCNH2
SCHEMBL2895523 0.74 P2RX7 (0.51) MEN1KMT2ACYP2D6ALDH1A1
SCHEMBL2891898 0.73 KCNH2 (0.42) MEN1KMT2ACYP2D6HRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US claimed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP claimed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP MEN1 4641/4885KMT2A 1314/4885CYP2D6 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.